Page 249«..1020..248249250251..260270..»

You do not have to use genetic engineering to benefit from genetics – The Economist

By Dr. Matthew Watson


The Economist
You do not have to use genetic engineering to benefit from genetics
The Economist
THE Japanese are great guzzlers of fish, but fish are in finite supply. And farming them to increase that supply can be tricky, because many species are susceptible to disease when crowded together. That fact is the impetus behind a study led by ...

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNEdEc1MZeJ10qZKxtGnVUsy11zZUg&url=http://www.economist.com/news/science-and-technology/21565576-you-do-not-have-use-genetic-engineering-benefit-genetics-high-tech

To Read More: You do not have to use genetic engineering to benefit from genetics – The Economist
categoriaUncategorized commentoComments Off on You do not have to use genetic engineering to benefit from genetics – The Economist | dataNovember 4th, 2012
Read All

Can genetic engineering make better flowers? – Mother Nature Network

By Dr. Matthew Watson


Mother Nature Network
Can genetic engineering make better flowers?
Mother Nature Network
But what about flowers? Not something that we can eat, or use as feed, but regular flowers grown and cut only to fill vases and occupy the hands of brides walking down the aisle. Decorative flowers are a frivolous crop, yet one that Americans spent $32 ...

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNEdE09A7XzMY2hBaJQXf_oLk1875A&url=http://www.mnn.com/green-tech/research-innovations/stories/can-genetic-engineering-make-better-flowers

To Read More: Can genetic engineering make better flowers? – Mother Nature Network
categoriaUncategorized commentoComments Off on Can genetic engineering make better flowers? – Mother Nature Network | dataNovember 4th, 2012
Read All

When Genetic Engineering Came Of Age – Forbes

By Dr. Matthew Watson


Forbes
When Genetic Engineering Came Of Age
Forbes
Today marks the 30th anniversary of an event that kicked off an important new era in drug therapies – the approval by the FDA of human insulin synthesized in genetically engineered bacteria. The saga is remarkable in several ways, not least of which is ...

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNHZ88pzg3V3KGNldEUch6pCVqn8eA&url=http://www.forbes.com/sites/henrymiller/2012/10/29/when-genetic-engineering-came-of-age/

To Read More: When Genetic Engineering Came Of Age – Forbes
categoriaUncategorized commentoComments Off on When Genetic Engineering Came Of Age – Forbes | dataNovember 4th, 2012
Read All

Thomas Petes, ‘monk of science’ and Duke geneticist, studies cancer through yeast – Duke Chronicle

By Dr. Matthew Watson


Duke Chronicle
Thomas Petes, 'monk of science' and Duke geneticist, studies cancer through yeast
Duke Chronicle
... 'monk of science' and Duke geneticist, studies cancer through yeast. Emily Yang/The Chronicle. Thomas Petes, Minne Geller professor of molecular genetics and microbiology, recently won the Thomas Hunt Morgan lifetime achievement award in genetics.

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNH9CWEKpW_DZLbwxjzTFf-v8TIohA&url=http://www.dukechronicle.com/article/thomas-petes-monk-science-and-duke-geneticist-stud

To Read More: Thomas Petes, ‘monk of science’ and Duke geneticist, studies cancer through yeast – Duke Chronicle
categoriaUncategorized commentoComments Off on Thomas Petes, ‘monk of science’ and Duke geneticist, studies cancer through yeast – Duke Chronicle | dataNovember 4th, 2012
Read All

A plan to stop cholera’s spread – Harvard Gazette

By Dr. Matthew Watson


Harvard Gazette
A plan to stop cholera's spread
Harvard Gazette
“The most likely conclusion is cholera was introduced in Haiti by a human,” said John Mekalanos, Lehman Professor of Microbiology and Molecular Genetics, in a talk called “River Monster: The Epidemiology, Ecology, and Pathobiology of Cholera." Haiti ...

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNEtyEgfPBKN9sorGzrn7I_7RNrR3A&url=http://news.harvard.edu/gazette/story/2012/10/a-plan-to-stop-choleras-spread/

To Read More: A plan to stop cholera’s spread – Harvard Gazette
categoriaUncategorized commentoComments Off on A plan to stop cholera’s spread – Harvard Gazette | dataNovember 4th, 2012
Read All

Sunny Side Up – Milwaukee Magazine

By Dr. Matthew Watson


Milwaukee Magazine
Sunny Side Up
Milwaukee Magazine
Son of a Parisian philosopher and a well-respected watercolor painter, Matthieu Ricard, who divides his time between molecular genetics and serving as an adviser to the Dalai Lama, may have the happiest brain on the planet, according to UW researcher ...

and more »

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNHOli4njoe_FO7KA7p0R3eNLkkziA&url=http://www.milwaukeemag.com/article/1112012-SunnySideUp

To Read More: Sunny Side Up – Milwaukee Magazine
categoriaUncategorized commentoComments Off on Sunny Side Up – Milwaukee Magazine | dataNovember 4th, 2012
Read All

A plea for population genetics – Discover Magazine (blog)

By Dr. Matthew Watson


Discover Magazine (blog)
A plea for population genetics
Discover Magazine (blog)
Look at the header of this website, or the background to my Twitter account. Mind you, I'm pathetically informed about molecular genetics, and don't have a strong interest in the topic! I did consider using the H.W.E. or the breeder's equation for the ...

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNEUpmtkJl8KOiRsMr3itHXBFCA2Gg&url=http://blogs.discovermagazine.com/gnxp/2012/10/a-plea-for-population-genetics/

To Read More: A plea for population genetics – Discover Magazine (blog)
categoriaUncategorized commentoComments Off on A plea for population genetics – Discover Magazine (blog) | dataNovember 4th, 2012
Read All

UNM doctors find the weak spots in viruses – KOB.com

By Dr. Matthew Watson


KOB.com
UNM doctors find the weak spots in viruses
KOB.com
"A lot of viruses have Achilles heels," says Dr. Bryce Chackerian, PhD, University of New Mexico Associate Professor of Molecular Genetics and Microbiology. "There are parts of a virus that always stay the same because they're really important for the ...

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNFBtbmtG6wa1kFGMkhG_iMg3lcYRQ&url=http://www.kob.com/article/stories/S2815672.shtml?cat%3D523

To Read More: UNM doctors find the weak spots in viruses – KOB.com
categoriaUncategorized commentoComments Off on UNM doctors find the weak spots in viruses – KOB.com | dataNovember 4th, 2012
Read All

GEN’s "Cellular Therapy Wave Finally Cresting". An overview and data set.

By Dr. Matthew Watson


We first provided a listing (with very few details) of industry-sponsored late-stage (pivotal, phase 3 and 2/3) cell therapy clinical trials on this blog late last year (see the posting here).

We are now pleased to we have worked with Genetic Engineering and Biotechnology News and Enal Razvi of Select Biosciences to provide an updated (as of June 2012) and more detailed listing of industry-sponsored late-stage (pivotal, phase 3 and 2/3) cell therapy clinical trials (excluding cell-based immunotherapies which we intend to cover in a follow-up article).

A link to the listing can be found in an article published today entitled "Cellular Therapy Wave Finally Cresting" found in the November 1, 2012 issue of GEN.  

While not my favorite title, the article is a brief - but we hope useful - overview of the sector and its pipeline.  It also provides a snapshot of the cell therapy products already in commercial distribution. 
Some will quibble about the numbers. Certainly others have published larger revenue numbers, for instance, but in our view these have almost always included revenue from cord blood banking which we have excluded.
We encourage you to read the article but for convenience here is a direct link to the spreadsheet.  Of course it's already out-dated but we'll do an update again soon here on this blog.


Hope this is useful.
--Lee


Source:
http://feedproxy.google.com/~r/CellTherapyBlog/~3/ctijFXeY01M/gens-cellular-therapy-wave-finally.html

To Read More: GEN’s "Cellular Therapy Wave Finally Cresting". An overview and data set.
categoriaRegenerative Medicine commentoComments Off on GEN’s "Cellular Therapy Wave Finally Cresting". An overview and data set. | dataNovember 4th, 2012
Read All

Study of California Stem Agency Likely to be Released in About a Month

By Dr. Matthew Watson


The $700,000, Institute of Medicine performance study of the $3 billion California stem cell agency is expected to be
released in late November or early December, the IOM said today.

In response to a question last week
from the California Stem Cell Report, Christine Stencel, senior media
relations officer for the IOM in Washington, D.C., briefly discussed
the release plans and the impact of the East Coast super-storm.
Here is the text of her response:

“The DC area escaped the worst of
Sandy’s thumping but nonetheless our schedules and planning have
been somewhat thrown off as we’re playing catch up after two days
of being shut down and some of our committee members and reviewers
are in the areas that got the brunt of the storm. We’re not sure
whether the storm will cause any delays in peer review, but we’re
working toward the goal of publicly releasing the report in late
November or early December. The study staff is working with committee
members to determine the best release format but I anticipate there
will be a press briefing. I’ll send a media advisory when we’ve
got all the details worked out.”

The stem cell agency is paying for the
report, which is examining the performance of the agency. The IOM
began its work in the summer of 2011.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/iNEFrnWvUO0/study-of-california-stem-agency-likely.html

To Read More: Study of California Stem Agency Likely to be Released in About a Month
categoriaStem Cell Therapy commentoComments Off on Study of California Stem Agency Likely to be Released in About a Month | dataNovember 4th, 2012
Read All

Geron Weighs Biotime Bid for hESC Biz

By Dr. Matthew Watson


Geron, Inc., of Menlo Park, Ca., said
today it is assessing an offer by two of its former executives to buy
the human embryonic stem cell program that it abandoned nearly a year
ago.
Geron startled the stem cell world,
including the $3 billion California stem cell agency, when it
jettisoned the first clinical trial of an hESC therapy for financial
reasons. The agency had loaned the company $25 million just a few
months earlier. Geron repaid the loan with interest.
Geron has been mum until today about the Oct. 18 offer by Biotime, Inc., of Alameda, Ca., which is headed
by Michael West, who founded Geron in 1990. Tom Okarma, president of
Geron from 1999 to 2011, is involved with West on the deal and is now
working at Biotime.
Geron's remarks came during a
conference call on its third quarter earnings. A spokesman said the
company is working with Biotime to “assess the feasibility” of
the proposal. He said the proposed transaction is complex and the
company is seeking “additional important details.”
The spokesman declined to offer any
additional comments on the Biotime proposal when questioned following
his initial statement.  
See here and here for earlier stories on the California Stem Cell Report on the Biotime offer. 

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/4JnJvoKwHpA/geron-weighs-biotime-bid-for-hesc-biz.html

To Read More: Geron Weighs Biotime Bid for hESC Biz
categoriaStem Cell Therapy commentoComments Off on Geron Weighs Biotime Bid for hESC Biz | dataNovember 4th, 2012
Read All

Biotime-Geron Deal Attracts Interest from Brit Investor

By Dr. Matthew Watson


A British investment trust that has
invested in Geron says it is going to take an advantage of an offer
by an Alameda firm that is seeking to acquire Geron's human embryonic
stem cell assets.

Jonathan C. Woolf, managing director
of British & American Investment Trust PLC, said last week in a letter to its
shareholders that it is disappointed in Geron's performance and the abandonment of its hESC program last November. The sudden halt to the
program and its historic clinical trial also surprised the California
stem cell agency, which had loaned Geron $25 million just a few
months earlier. The agency has expressed an interest in continuing the trial.
Woolf said,

“We have been highly critical of
Geron management's decisions and strategy over the past 20 months, in
particular the decision in November 2011 to abruptly exit Geron's
regenerative medicine (stem cell) business in which it was the
acknowledged world leader. Since that time, Geron management has
attempted to sell or partner this business but to date has been
unable to announce any progress on this.”

Woolf's trust is not listed as a major
Geron shareholder by Morningstar, but Woolf said 17 percent of his firm's
investments are in the Menlo Park, Ca., company. The
specific size of the trust's holdings in Geron was not immediately
known.
Woolf pointed to the offer by Biotime,
Inc
., of Alameda, Ca., as a way for Geron shareholders to benefit. On
Oct. 18, Biotime proposed a complicated deal in which it would
acquire Geron's hESC program. Biotime's president, Michael West,
founded Geron in 1990. The head of the Biotime subsidiary that would acquire
the Geron assets is Tom Okarma, who was CEO of Geron from 1999 to 2011. (Here are links to brief stories on the offer: Fiercebiotech, New Scientist.)
In his letter, Woolf noted Geron's
declining stock performance. He said he is “seriously concerned”
that Geron has failed to find a buyer for the assets. Woolf said,

“These now dormant and untended
assets are inevitably losing value as competitors make progress in
Geron's absence from the field and patent protection periods
decline.”

Woolf continued,

“We believe BioTime's proposals would
make Geron's stem cell assets in combination with those of BioTime
once again the world's leading stem cell business with sufficient
resources to recommence the discontinued programmes and develop the
business further into the medium term.”

Woolf urged Geron directors and other
Geron shareholders to work with Biotime to complete the deal. Geron
has not commented on the offer.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/va_Yea0dbF8/biotime-geron-deal-attracts-interest.html

To Read More: Biotime-Geron Deal Attracts Interest from Brit Investor
categoriaStem Cell Therapy commentoComments Off on Biotime-Geron Deal Attracts Interest from Brit Investor | dataNovember 4th, 2012
Read All

Confessions Of An Organic-Munching Genetic Engineer (No On Prop 37 As … – Science 2.0

By Dr. Matthew Watson


Kansas City Star
Confessions Of An Organic-Munching Genetic Engineer (No On Prop 37 As ...
Science 2.0
The AAAS says mandatory labeling is reserved for potential dangers, but genetic engineering is as safe as conventional breeding. Therefore, labels would falsely imply something wrong with GMO products. The UCS, on the other hand, supports GMO labeling ...
Safety of genetically modified foods is debated in CaliforniaKansas City Star
GMO Labeling: Does Proposition 37 Falsely Alarm or Empower Consumers?About - News & Issues
Citizen campaign to label GMO foods puts industry on defense, decades after ...Monterey County Weekly
North County Times (blog) -San Mateo Daily Journal -Food Consumer
all 196 news articles »

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNFQeRY5lLUcw7RlJp-R2zmtr7Eolw&url=http://www.science20.com/caution_pondering_scientist_ahead/confessions_organicmunching_genetic_engineer_no_prop_37_written-95993

To Read More: Confessions Of An Organic-Munching Genetic Engineer (No On Prop 37 As … – Science 2.0
categoriaUncategorized commentoComments Off on Confessions Of An Organic-Munching Genetic Engineer (No On Prop 37 As … – Science 2.0 | dataNovember 4th, 2012
Read All

cryocell | Umbilical Cord Stem Cells – Hope For a Better Tomorrow With Cord Blood Banking – Video

By Dr. Matthew Watson


cryocell | Umbilical Cord Stem Cells - Hope For a Better Tomorrow With Cord Blood Banking
http://www.cordbloodrecommendation.com However, the fees from bank to bank are pretty similar across the board. It is ready-to-use, as it is stored frozen after collecting and testing it. However, this blood can be used for non-family members and is being used to treat diseases and save lives. Secondly they regenerate cells to treat heart and circulatory diseases. Swarms of people are visiting the hospital to know more about preservation and how it is going to be beneficial for them in times of medical emergencies. The latter comes under much scrutiny and debate. However, looking at the benefit your child or may be his siblings may get 20 years down the line, you can definitely think of it as an insurance premium. 4. She was in the advanced stages of Parkinson and was looking for treatment options. How Can I Save My Baby #39;s Cord Blood?You can save it by storing it in a private cord blood bank, but if you do not save it, it will be discarded after birth. The proportion of unsuccessful searches is even greater among patients not of Northern European descent. Compared to bone marrow stem cells, cord blood stem cells are easier to harvest because they are easily obtainable from placenta after delivery and so do not involve a surgical procedure. The transplants are used to treat diseases as well as immune system problems. Most, if not all, of the major cord blood banking companies allow you to create a gift registry - similar to the popular registries at baby retailers - so that ...From:luisantafeViews:0 0ratingsTime:01:31More inTravel Events

Read the original:
cryocell | Umbilical Cord Stem Cells - Hope For a Better Tomorrow With Cord Blood Banking - Video

To Read More: cryocell | Umbilical Cord Stem Cells – Hope For a Better Tomorrow With Cord Blood Banking – Video
categoriaBone Marrow Stem Cells commentoComments Off on cryocell | Umbilical Cord Stem Cells – Hope For a Better Tomorrow With Cord Blood Banking – Video | dataNovember 3rd, 2012
Read All

Irvine Scientific Offers Cell Therapy Products

By Dr. Matthew Watson

SANTA ANA, Calif.--(BUSINESS WIRE)--

Irvine Scientific, a leading cell culture media/ medical device company for more than 40 years, announced their newly launched cell therapy PRIME-XV product portfolio as part of the companys commitment to accelerate basic research and clinical applications in cell therapy and regenerative medicine. Using their expertise in cell culture media development, PRIME-XV products were designed to function as part of an integrated workflow solution in culturing primary cells, where all products have been pre-validated to decrease end user qualification time. Initially, PRIME-XV products will comprise of a serum-free medium for the expansion of human mesenchymal stromal/ stem cells (MSCs), biopreservation solutions and extracellular matrix proteins. However, Irvine Scientific intends to expand this product line to offer other cell culture media and reagents, such as stem cell qualified fetal bovine serum, tumorsphere and neural progenitor cell expansion media. Examples of existing PRIME-XV products include:

PRIME-XV MatrIS F: a recombinant human matrix protein intended for the culture of human stem/ progenitor cells under serum-free conditions. PRIME-XV MatrIS F provides an alternative substrate to the PRIME-XV Human Fibronectin product, which has a wide variety of applications in primary cell spreading and attachment.

PRIME-XV MSC EXPANSION SFM: a complete, serum-free expansion medium specifically designed for the culture of primary human MSCs derived from bone marrow and adipose tissues. This medium is supplied as a convenient one 250mL bottle and is ready-to-use without the need of additional cytokine/ growth factor supplements. MSCs cultured in PRIME-XV MSC EXPANSION SFM out performed serum-containing medium as well as leading competitors in cell expansion studies without losing their multipotent characteristics or immune modulation functions.

PRIME-XV Hypothermic Biopreservation Solution: a protein-free, defined solution intended for storage and stable shipping of cells and tissue samples under hypothermic (2-8C) condition. By preserving cells above freezing temperature, it reduces cellular stress response associated from chilling and re-warming of cells and tissues, and retains high culture viabilities after recovery. Simply replace the culture medium with this animal component-free, cGMP manufactured product for short term storage. To recover from preservation, PRIME-XV Hypothermic Biopreservation Solution is removed and replaced with growth medium of choice.

As an alternative to the PRIME-XV Hypothermic Biopreservation Solution, Irvine Scientific also carries a protein-free, defined PRIME-XV Cryogenic Preservation Solution, which allows for cryopreservation of biologics at -80C to -196C.

About Irvine Scientific

Irvine Scientific, a member of JX group, is a worldwide leader in the design, manufacture and distribution of medical devices, including Cell Therapy, Industrial Cell Culture, Cytogenetic and Assisted Reproductive Technology products. We are a large scale producer of advanced quality cell culture media for the cell therapy, industrial bioprocess, medical and diagnostic markets. Our companys extensive experience in the design of culture media, compliance with ISO and FDA regulations for class II/III medical devices and industrial scale manufacturing capacity provides our customers with unique capabilities and support. Irvine Scientific delivers products worldwide to the biopharmaceutical industry, research and medical laboratory communities.

For more information:

- Visit http://www.irvinesci.com

More:
Irvine Scientific Offers Cell Therapy Products

To Read More: Irvine Scientific Offers Cell Therapy Products
categoriaUncategorized commentoComments Off on Irvine Scientific Offers Cell Therapy Products | dataNovember 3rd, 2012
Read All

FAQ-3 of 19- How Do Stem Cells Work? – Video

By Dr. Matthew Watson


FAQ-3 of 19- How Do Stem Cells Work?
youtu.be Stem Cell Proving Great Help for AIDS Sufferers Who Use Stem Cell Therapy, and this short video shows how, in a fun visual way that explains the #39;homing mechanism #39; that guides stem cells to their target (ailing, sick, dysfunctional) organs, where the stem cells differentiate, and live to strengthen and heal the previously diseased organ. For more information, visit StemCell-Asia.info today.From:Harvey WallbangerViews:8 0ratingsTime:01:01More inScience Technology

Read the original here:
FAQ-3 of 19- How Do Stem Cells Work? - Video

To Read More: FAQ-3 of 19- How Do Stem Cells Work? – Video
categoriaUncategorized commentoComments Off on FAQ-3 of 19- How Do Stem Cells Work? – Video | dataNovember 3rd, 2012
Read All

FAQ-4 19- What Chance Stem Cells HELP Me After Stem Cell Therapy? – Video

By Dr. Matthew Watson


FAQ-4 19- What Chance Stem Cells HELP Me After Stem Cell Therapy?
youtu.be As differentiated or undifferentiated, whether from sheep stem cells or from rabbit; delivered frozen or fresh, today #39;s stem cell therapies are showing real promise and helping HIV-AIDS sufferers around the world, today! Cautious not to claim they can cure ANYTHING, today #39;s ethical clinics offer hope for AIDS-HIV sufferers worldwide, although the one Thai clinic licensed by the German stem cell technique is in Bangkok. For information to help you make an informed, personal decision, check out StemCell-Asia.info today.From:John PepperViews:0 0ratingsTime:01:38More inPeople Blogs

The rest is here:
FAQ-4 19- What Chance Stem Cells HELP Me After Stem Cell Therapy? - Video

To Read More: FAQ-4 19- What Chance Stem Cells HELP Me After Stem Cell Therapy? – Video
categoriaUncategorized commentoComments Off on FAQ-4 19- What Chance Stem Cells HELP Me After Stem Cell Therapy? – Video | dataNovember 3rd, 2012
Read All

FAQ-4 19- What Chances for Stem Cell Success When I Get Stem Cell Therapy? – Video

By Dr. Matthew Watson


FAQ-4 19- What Chances for Stem Cell Success When I Get Stem Cell Therapy?
youtu.be Whether as differentiated or undifferentiated, whether from sheep stem cells or from rabbit stem cells; delivered frozen or fresh, today #39;s stem cell therapies are showing real promise and helping HIV-AIDS sufferers around the world, today! Cautious not to claim they can cure ANYTHING, today #39;s ethical clinics offer hope for AIDS-HIV sufferers worldwide, although the one Thai clinic licensed by the German stem cell technique is in Bangkok. For information to help you make an informed, personal decision, check out StemCell-Asia.info today.From:VeteransRecallViews:1 0ratingsTime:01:38More inPeople Blogs

Originally posted here:
FAQ-4 19- What Chances for Stem Cell Success When I Get Stem Cell Therapy? - Video

To Read More: FAQ-4 19- What Chances for Stem Cell Success When I Get Stem Cell Therapy? – Video
categoriaUncategorized commentoComments Off on FAQ-4 19- What Chances for Stem Cell Success When I Get Stem Cell Therapy? – Video | dataNovember 3rd, 2012
Read All

FAQ-3 of 19: How Does Stem Cell Therapy Work to Get Stem Cells to Organs – Video

By Dr. Matthew Watson


FAQ-3 of 19: How Does Stem Cell Therapy Work to Get Stem Cells to Organs
youtu.be A video describing how stem cells home in on their injured organs, find their place and then differentiate into the cells that the hurt or diseased or dysfunctional organ NEEDS. Specific chemical markers act as #39;homing beacons #39; for the undifferentiated stem cells, bringing the vibrant, healthy stem cells STRAIGHT to the diseased organ, to begin rejuvenation. For more on this and how stem cells MIGHT help you or your loved one, go to StemCell-Asia.info now.From:Harvey WallbangerViews:1 0ratingsTime:01:06More inScience Technology

Read more:
FAQ-3 of 19: How Does Stem Cell Therapy Work to Get Stem Cells to Organs - Video

To Read More: FAQ-3 of 19: How Does Stem Cell Therapy Work to Get Stem Cells to Organs – Video
categoriaUncategorized commentoComments Off on FAQ-3 of 19: How Does Stem Cell Therapy Work to Get Stem Cells to Organs – Video | dataNovember 3rd, 2012
Read All

FAQ-4 of 19: What Chance of Stem Cell Success When I Opt for Stem Cell Therapy? – Video

By Dr. Matthew Watson


FAQ-4 of 19: What Chance of Stem Cell Success When I Opt for Stem Cell Therapy?
youtu.be This short video describes how stem cells home in on their injured organs, find their place and then differentiate into the cells that the hurt or diseased or dysfunctional organ NEEDS. For more on this and how stem cells MIGHT help you or your loved one, go to StemCell-Asia.info now.From:Harvey WallbangerViews:2 0ratingsTime:01:28More inPeople Blogs

Continue reading here:
FAQ-4 of 19: What Chance of Stem Cell Success When I Opt for Stem Cell Therapy? - Video

To Read More: FAQ-4 of 19: What Chance of Stem Cell Success When I Opt for Stem Cell Therapy? – Video
categoriaUncategorized commentoComments Off on FAQ-4 of 19: What Chance of Stem Cell Success When I Opt for Stem Cell Therapy? – Video | dataNovember 3rd, 2012
Read All

Page 249«..1020..248249250251..260270..»


Copyright :: 2025